GP新辅助化疗联合手术治疗非小细胞肺癌临床评价  

Clinical Evaluation of GP Neoadjuvant Chemotherapy Combined with Surgery in the Treatment of Non-Small Cell Lung Cancer

作　　者：何纯 刘铮 谭小伟 冯超 张绍宇 刘冰[2] HE Chun;LIU Zheng;TAN Xiaowei;FENG Chao;ZHANG Shaoyu;LIU Bing(Department of Surgery,903 Hospital,Mianyang,Sichuan,China 621700;Department of Infectious Disease,Mianyang 404 Hospital,Mianyang,Sichuan,China 621000)

机构地区：[1]九〇三医院外科,四川绵阳621700 [2]四川绵阳四〇四医院感染科,四川绵阳621000

出　　处：《中国药业》2022年第16期86-88,共3页China Pharmaceuticals

基　　金：四川省卫生和计划生育委员会科研课题[18PJ342]。

摘　　要：目的探讨吉西他滨和顺铂(GP)新辅助化学药物治疗(简称化疗)联合手术治疗非小细胞肺癌(NSCLC)的临床疗效及对患者免疫功能和肿瘤标志物的影响。方法选取九○三医院2019年2月至2021年2月收治的NSCLC患者102例,按治疗方式的不同分为观察组和对照组,各51例。两组患者均行肺癌根治术治疗,观察组患者加用GP新辅助化疗,以2周为1个化疗周期,持续化疗2个周期。结果观察组总缓解率为94.12%,明显高于对照组的60.78%(P<0.05)。治疗后,观察组患者癌胚抗原、糖类抗原125、癌抗原19-9水平均明显低于对照组,T淋巴细胞亚群中CD_(3)^(+)及CD_(4)^(+)水平的降幅均明显小于对照组(P<0.05)。观察组患者不良反应发生率为7.84%,明显低于对照组的19.61%(P<0.05)。结论GP新辅助化疗联合手术治疗NSCLC,可降低患者肿瘤标志物水平及药品不良反应发生率,对免疫功能的影响较小。Objective To investigate the clinical efficacy of gemcitabine and cisplatin(GP)neoadjuvant chemotherapy combined with surgery in the treatment of non-small cell lung cancer(NSCLC)and its effect on the levels of immune function and tumor markers in patients.Methods A total of 102 patients with NSCLC admitted to the 903 Hospital from February 2019 to February 2021 were selected and divided into the observation group and the control group according to different treatment methods,with 51 cases in each group.The patients in the two groups were treated with radical resection of lung cancer,on this basis,the patients in the observation group were treated with GP neoadjuvant chemotherapy,and they were given continuous chemotherapy for two cycles with two weeks as a chemotherapy cycle.Results The total remission rate in the observation group was 94.12%,which was significantly higher than 60.78% in the control group(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and cancer antigen 19-9(CA19-9)in the observation group were significantly lower than those in the control group,and the decrease of CD_(3)^(+) and CD_(4)^(+) in T lymphocyte subsets in the observation group was significantly less than that in the control group(P<0.05).The incidence of adverse drug reactions in the observation group was 7.84%,which was significantly lower than 19.61% in the control group(P<0.05).Conclusion GP neoadjuvant chemotherapy combined with surgery in the treatment of NSCLC can reduce the level of tumor markers and the incidence of adverse drug reactions,and it has less impact on immune function.

关 键 词：GP方案 新辅助化疗 手术 非小细胞肺癌 免疫功能 肿瘤标志物 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]